Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
10 Dezembro 2024 - 8:26PM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today provided an update on its engagement
with UnitedHealthcare (UNH) following the Nov 1, 2024 publication
of its updated medical policy restricting access to multi-gene
panel pharmacogenetic tests, including Myriad’s GeneSight test,
under its commercial and individual exchange benefit plans,
effective January 1, 2025.
Since the announcement, Myriad has actively engaged in
constructive dialogue with UNH regarding the clinical evidence
supporting Myriad’s proprietary and clinically differentiated
mental health medication test, GeneSight, including presenting
additional clinical data to UnitedHealthcare for its further review
and consideration. Myriad has requested that UHC enrollees continue
to have access to the test in 2025, especially in the primary care
setting where a significant majority of antidepressants are
prescribed 1.
“Following the tragic death of UnitedHealthcare CEO Brian
Thompson on December 4th, we extend our deepest condolences to
Brian’s family and all employees of UnitedHealthcare. Soon, at the
appropriate time, we plan to continue our dialogue with UNH and
other key stakeholders,” said Paul J. Diaz, President and CEO,
Myriad Genetics. “We desire resolution ahead of year-end, but
discussions may extend into early 2025. We remain steadfast in our
confidence in the clinical validity and utility of GeneSight, which
we believe is supported by clinical evidence, including
peer-reviewed research studies.”
During Myriad’s third quarter earnings call held on November 6,
2024, the company provided an estimate of the 2024 financial impact
of UNH’s updated medical policy. While Myriad continues to engage
with UNH, the company reaffirms this estimate.
About the GeneSight® Psychotropic
TestThe GeneSight Psychotropic test from Myriad Genetics
is the category-leading pharmacogenomic test for more than 60
medications commonly prescribed for depression, anxiety, ADHD, and
other psychiatric conditions. The GeneSight test can help inform
clinicians about how a patient’s genes may impact how they
metabolize and/or respond to certain psychiatric medications. Tens
of thousands of clinicians have ordered the GeneSight test for
almost three million patients in order to receive genetic
information that is unique to each patient. The GeneSight test
supplements other information considered by a clinician as part of
a comprehensive medical assessment. The clinical validity, clinical
utility and economic utility of the GeneSight test have been
evaluated in multiple peer-reviewed publications. Learn more
at GeneSight.com.
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor Statement This press
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
statements regarding the company’s plan to continue its dialogue
with UNH and other key stakeholders and the company’s confidence in
the clinical validity and utility of GeneSight, which the company
believes is supported by clinical evidence, including peer-reviewed
research studies. These “forward-looking statements” are
management’s expectations of future events as of the date hereof
and are subject to known and unknown risks and uncertainties that
could cause actual results, conditions, and events to differ
materially and adversely from those anticipated. Such factors
include those risks described in the company’s filings with the
U.S. Securities and Exchange Commission, including the company’s
Annual Report on Form 10-K filed on February 28, 2024, as well as
any updates to those risk factors filed from time to time in the
company’s Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. Myriad is not under any obligation, and it expressly disclaims
any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise
except as required by law.
1 Majtabai R, et al. J Clin Psychiatry. 2008
Jul;69(7):106574.
Investor Contact Matt Scalo (801)
584-3532 IR@myriad.com
Media Contact Glenn Farrell (385)
318-3718 PR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024